Hot Investor Mandate: Family Office-Backed Life Sciences Fund Invests Across Therapeutics, Diagnostics, and Digital Health Globally

12 Nov

This life sciences-focused investment firm backed by a prominent family office is actively investing in life science and healthcare companies across the globe, with a focus on those that are based near their headquarters. 

The firm invests in early-stage healthcare companies, with interest in therapeutics, diagnostics, and digital health. It is agnostic to technology type and therapeutic indication, but prefers opportunities with robust pre-clinical data. The firm is open to both pre-clinical and clinical-stage projects, though it does not invest in medical device companies at this time. 

The firm is focused on supporting innovative technologies and is open to partnering with both first-time and experienced founding teams. It is flexible in its role, willing to act as either a lead investor or a co-investor, depending on the structure and needs of the financing round.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

The Real “Secret Sauce” for Startup Success 

4 Nov

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wp

Many entrepreneurs hope there’s a “secret sauce” or formula for success. In reality, it’s much more about attitude and persistence than any secret trick. Across hundreds of startups we’ve met, the most consistent trait among successful founders is determination — the willingness to try every avenue, face setbacks head-on, and keep finding new ways forward. 

One of the toughest challenges founders face is getting in front of investors. Whether it’s outreach for a partnering event, sending a cold email, or following up after a meeting, responses can be few and far between. This silence often feels discouraging — some see it as rejection or assume something’s wrong with their company. More often than not, though, it’s simply a matter of timing, clarity, or persistence. 

At RESI, we’ve seen time and again that the entrepreneurs who keep going — who adapt and stay visible — are the ones who eventually break through. Here are a few strategies that can make the difference: 

  1. Keep Following Up

Persistence pays off. One CEO sent 20 follow-up emails over six months before finally securing a meeting. The investor only vaguely remembered the company but appreciated the founder’s consistency and determination. The lesson? As long as you haven’t heard “no,” keep reaching out. You’re not being a nuisance — you’re demonstrating commitment. 

  1. Find Another Approach

When one CEO didn’t get as many meetings as hoped at a RESI event, he asked which investors from his target list had checked in. Armed with that information, he sought them out while networking, leading to several meaningful conversations. Whether it’s catching investors after a panel, reaching out via LinkedIn, or changing your communication style, adapt until you make contact. 

Register for RESI London Register for RESI JPM
  1. Maximize Every Opportunity

Visibility matters. One Innovator’s Pitch Challenge (IPC) participant hosted a raffle at their poster to attract attendees. The result? Buzz around their company, new ad hoc meetings, and ultimately, an IPC win. By creating a memorable experience, they stood out in a crowded environment — and investors took notice. 

Appy to Pitch at RESI London Appy to Pitch at RESI JPM

Takeaway 

There’s no shortcut to building investor relationships — but determination, creativity, and consistent action go a long way. Keep putting yourself and your company out there, follow up with intention, and make every opportunity count. At RESI, we see it time and again: the founders who stay proactive and visible are the ones who get results. 

Tags: , , , ,

RESI JPM 2026: A Global Hub for Life Science Connections 

4 Nov

By Matt Stanton, VP Sales US West, Central and South America, LSN

The Redefining Every Stage of Investment (RESI) Conference returns to San Francisco for RESI JPM 2026, taking place January 12–13 at the San Francisco Marriott Marquis. This two-day in-person event will be followed by three days of online partnering on January 14, 19, and 20, providing multiple opportunities to connect with investors, strategic partners, and early-stage innovators across biotech, medtech, diagnostics, and digital health.

RESI JPM is one of the the biggest and well attended investor partnering events held concurrently alongside JP Morgan Healthcare Week , RESI JPM serves as an high-impact venue for early-stage companies to meet investors and strategic partners in a focused, partnering-driven environment. Previous RESI JPM conferences have drawn more than a thousand participants, including over 700 early-stage life science investors, innovators, and industry leaders.

This year, RESI JPM 2026 welcomes companies and delegations representing more than 36 countries, reflecting the truly global reach of the RESI community. The event brings together entrepreneurs and investors from every major life science hub, creating a dynamic platform for cross-border collaboration and innovation.

We’re honored to host international cohorts from: 

  • Brisbane Economic Development Agency (BEDA) – Government Organization, Australia
  • Kobe Biomedical Innovation Cluster (KBIC) – Incubator/Accelerator, Japan
  • Monash University – Tech Hub, Australia
  • Ontario (Canada)
  • Enterprise Singapore
  • Ganesha Lab – Latin America
  • Apex Brasil
  • One Nucleus (UK)
  • O2h (UK)

These groups join a growing network of innovators supported by Life Science Nation’s (LSN) global ecosystem. LSN and the RESI Conference Series have built connections spanning every continent, linking life science startups with investors ranging from seed-stage venture funds to corporate pharma and strategic partners. The international participation seen at RESI JPM underscores LSN’s mission to connect early-stage technologies with capital and expertise across borders.

We are also grateful for the ongoing collaboration of our global partners, including Freemind, Biocat, BioPartner UK, Life Science British Columbia, Arizona Bio, Biotech Gate, MaRS Discovery District, MassChallenge, and Eurasanté — and many more.

Join us in San Francisco and online for RESI JPM 2026 to engage with the global life science community and accelerate your innovation journey. There is still time to apply to pitch in the Innovator’s Pitch Challenge, where startups gain exposure to investors and industry experts providing valuable feedback and connections.

To date, 90 companies have reported raising $1.29 billion from connections that began at RESI — your next breakthrough could be just one conversation away.

Register for RESI JPM Appy to Pitch at RESI JPM

Tags: , , , ,

Beyond Borders: How to Prepare for Partnering Success at RESI London in the “Winter” 

4 Nov

By Greg Mannix, VP, EMEA Business Development, LSN

When was the last time you spoke directly with an investor? Or better yet how often do you have the chance to meet with multiple qualified investors in a single day? 

In today’s challenging investment climate, life science startups can’t afford to slow down their fundraising efforts. Capital is still out there, but it requires thinking beyond borders. 

To thrive in this “winter,” fundraising CEOs must: 

  • Step outside their regional ecosystems 
  • Build global visibility 
  • Connect directly with investors, in-licensors, and strategic partners who are still actively deploying capital 

That is exactly what RESI London 2025 is designed to help you do. 

Why Partnering Conferences Matter 

Partnering conferences, like RESI, give startups a fast, efficient way to meet investors who are aligned with their technology, stage, and strategy. Instead of spending months chasing introductions, companies can meet dozens of potential partners across two or three days. These concentrated interactions save time, reduce travel costs, and dramatically increase fundraising success rates. 

How to Prepare for a Partnering Conference 

Preparation determines success. Before meetings begin, make sure your company profile, pitch deck, and meeting strategy are ready. 

Join Life Science Nation’s free Partnering Tutorial Webinar on Monday, November 10 at 10 AM Eastern to learn how to navigate the RESI Partnering Platform, refine your outreach, and get ready to meet investors. 

Sign Up Free Webinar

RESI’s Unique Approach to Partnering 

Unlike most conferences, which offer only basic scheduling tools, the RESI Partnering Platform is built specifically for early-stage life sciences. It features a curated database of investor profiles gathered through direct interviews. Startups can filter investors by type, indication, and development stage to find their most relevant matches. This data-driven approach makes your meetings more targeted and impactful. 

RESI Survival Guide 

To help fundraising executives make the most of RESI, LSN developed the RESI Survival Guide, outlining five essential steps to partnering success. It covers how to identify the right investors, structure your day, and follow up effectively after the event. 

Ways to Partner: Standard vs. Premier Access 

Premier Access attendees enjoy additional benefits, including early access to investor profiles, enhanced visibility, and dedicated support from the LSN team. Whether you choose Standard or Premier, every investor profile on the RESI platform is verified and interviewed to ensure a high-quality partnering experience. 

Register for RESI London Appy to Pitch at RESI London

Tags: , , , , ,

Hot Investor Mandate: Europe-Based VC Firm Invests in Early-Stage Companies in Tech-Enabled Life Science and Healthcare Companies

4 Nov

 
This growth-focused investment firm is headquartered in Europe, and was founded by entrepreneurs who previously built and exited a unicorn multinational company. With a renewed mission to drive innovation and growth, the firm targets both early-stage life science ventures and established professional service providers. 

In the early-stage segment, the firm typically invests up to €500K in Series A rounds and makes smaller allocations at the Seed stage. The investment strategy centers on innovative, tech-enabled, and service-oriented companies within the life sciences and healthcare sectors. While the firm is open to early-stage opportunities, it prefers companies with a proven business model and a clear path to scale. 

The firm is eager to partner with strong management teams developing solutions that address unmet needs with a compelling value proposition. Most investments are made as part of a syndicate with institutional venture capital firms, and the firm contributes beyond capital by offering deep sector expertise, an extensive network, and a strong entrepreneurial track record. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Private Investment Firm Invests in Seed to Series A Medical Devices, Diagnostics, and Digital Health Companies in North America

4 Nov

An investment firm headquartered in the US focuses on healthcare companies across the seed, venture, and growth stages. The firm typically provides seed and Series A equity financing ranging from $100K to $1M per portfolio company. While the firm often acts as a lead investor, it is also open to participating in syndicated rounds. The firm is open to investment opportunities throughout North America. The firm is actively seeking new investments. 

Current areas of interest include medical devices, diagnostics, digital health, and healthcare-focused software. The firm is also open to reformulated or repurposed drugs, particularly those with reduced development risk. In the medical device category, the firm remains opportunistic across subsectors, with a preference for products that have a prototype and follow the 510(k) regulatory pathway. The firm is indication-agnostic, with interest that includes orphan diseases and the dental field. 

The firm places a strong emphasis on working with experienced management teams and may take a board seat when appropriate. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: VC Firm Headquartered in Asia Seeks Early-Stage Life Science Companies in the Intersection of Science and Technology

4 Nov

 
This venture capital firm focuses on breakthrough technologies transforming healthcare and typically invests at the pre-seed, seed, and pre-Series A stages. The firm is backed by limited partners from within the healthcare industry, reinforcing its domain expertise and strategic alignment with clinical innovation. 

The firm targets early-stage life science startups working at the intersection of cutting-edge science and healthcare applications. Areas of interest include genomic technologies, synthetic biology, digital health, machine learning and artificial intelligence, therapeutics, and diagnostics. In therapeutics, the firm focuses on pre-IND assets, while for technologies regulated as medical devices, the firm prioritizes smart devices at the pre-commercial stage. 

With a team that brings a strong clinical perspective, the firm actively supports its portfolio companies through clinical development and has a history of helping academic scientists translate research into commercial ventures. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

← Older Entries
Newer Entries →